Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients

NCT05355298 is registered in ClinicalTrials.gov with Amplia Therapeutics Limited as lead sponsor.

NCT NCT05355298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05355298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients
Lead sponsor
Amplia Therapeutics Limited
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 31, 2022
Completion date
February 1, 2027
Enrollment
62 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic ductal adenocarcinoma, pdac